The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Key takeaways of Q3FY22 quarter & conference call highlights
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Acute therapies continue to report strong growth compared to chronic ones.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
India business contributes to a stellar performance
India business is growing as per projections; whereas US business will bounce back soon.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)